Evaluation of childhood Expanded Programme on Immunization (EPI) vaccination effectiveness provides objective, laboratory-based evidence of whether routine immunization schedules induce and sustain protective immunity in infants and children. This technical article outlines the sample types, serological testing panels, laboratory methods, statistical evaluation criteria, and practical applications involved in assessing immune responses to childhood vaccines such as hepatitis B, poliovirus, DTP, measles-rubella, Japanese encephalitis, and hepatitis A vaccines. All testing described can be performed by accredited third-party laboratories in accordance with ISO 15189, ISO/IEC 17025, WHO technical guidance, and relevant GB national standards.
Technical Overview
The Expanded Programme on Immunization (EPI) is the systematic schedule of routine vaccines administered to children from birth through school age. Vaccination effectiveness evaluation integrates laboratory-based serological testing, vaccination coverage audits, and epidemiological surveillance to verify that the immunization program achieves and maintains protective antibody levels at both the individual and population levels.
The evaluation scope typically covers the routine childhood vaccine panel: hepatitis B vaccine (HepB), bacillus Calmette-Guérin vaccine (BCG), inactivated and bivalent oral poliovirus vaccines (IPV/bOPV), diphtheria-tetanus-acellular pertussis vaccine (DTaP), measles-rubella combination vaccine (MR) or measles-mumps-rubella vaccine (MMR), Japanese encephalitis vaccine (JE), hepatitis A vaccine (HepA), and group A and group A+C meningococcal polysaccharide vaccines (MPV-A, MPV-AC).
A complete effectiveness assessment is structured around five dimensions:
- Immunogenicity and seroprevalence: quantification of vaccine-induced antibodies and comparison against internationally recognized protective thresholds.
- Vaccination coverage: administrative coverage rates, survey-based coverage estimates, and immunization information system data verification.
- Vaccine quality and cold-chain integrity: potency verification of retained samples when temperature excursions are suspected.
- Safety surveillance: laboratory work-up of adverse events following immunization (AEFI).
- Program impact: correlation of serological results with the incidence of vaccine-preventable diseases.
Testing is performed by accredited third-party laboratories operating in conformance with ISO 15189 for medical laboratories or ISO/IEC 17025 for general testing competence, with assay calibration traceable to WHO International Standards and methods aligned with WHO technical manuals and applicable GB national and WS health industry standards.
Testing Samples
Serum Specimens
Venous blood of 2–3 mL from infants and 3–5 mL from older children is collected in sterile tubes without anticoagulant. Samples are centrifuged at 1,500–3,000 × g for 10–15 minutes, and the separated serum is aliquoted into cryovials. Serum is stored at 2–8 °C for short-term processing (within 48 hours) or at −20 °C to −70 °C for long-term storage. Hemolysis, microbial contamination, and repeated freeze–thaw cycles must be avoided, and transport under cold chain with continuous temperature logging is required.
Dried Blood Spot (DBS) Cards
Finger-prick or heel-prick blood of approximately 50–100 µL per spot is applied to standardized filter paper cards, air-dried for a minimum of 4 hours, and individually packaged with desiccant. DBS sampling is particularly suitable for large-scale community serosurveys in remote areas, and validated DBS-based assays are available for anti-HBs, anti-measles IgG, and anti-rubella IgG determinations.
Pathogen Surveillance Specimens
For case-based surveillance linked to the effectiveness evaluation, stool specimens (collected within 14 days of onset for acute flaccid paralysis cases and healthy contacts), oropharyngeal and nasopharyngeal swabs, urine samples, and cerebrospinal fluid may be submitted for virus isolation, molecular detection, and sequencing to identify circulating or vaccine-derived strains.
Immunization Program Data
Vaccination certificates, immunization information system records, vaccine lot numbers, cold-chain temperature logs, and coverage survey questionnaires are collected as data samples to cross-verify documented vaccination status against laboratory-confirmed immunity.
Vaccine Retention Samples
Sealed vials from suspect lots or from cold-chain segments with recorded temperature excursions are retained for potency testing, including antigen content determination by immunoassay and infectious titer determination for live attenuated vaccines.
Testing Items
Serological panels are reported in quantitative units (mIU/mL or IU/mL) traceable to WHO International Standards, or as reciprocal dilution titers for functional neutralization assays, and interpreted against established protective thresholds.
Humoral Immunity Panels
- Anti-HBs quantification: protective immunity defined as anti-HBs ≥ 10 mIU/mL; results below this threshold indicate non-protective response and the need for booster evaluation.
- HBsAg, HBeAg, and anti-HBc: differential markers distinguishing vaccine-induced immunity from natural hepatitis B virus infection, essential for mother-to-child transmission evaluation.
- Poliovirus neutralizing antibodies (types 1, 2, and 3): protective titer defined as a reciprocal dilution of ≥ 1:8 in the microneutralization assay.
- Diphtheria and tetanus antitoxin IgG: minimum protective level of 0.01 IU/mL, with ≥ 0.1 IU/mL recommended for sustained long-term protection.
- Bordetella pertussis anti-PT and anti-FHA IgG: indicators of vaccine response and markers for recent infection when anti-PT IgG exceeds approximately 100 IU/mL in the absence of recent vaccination.
- Measles virus IgG: protective level generally accepted as ≥ 200 mIU/mL by ELISA, confirmable by plaque reduction neutralization.
- Rubella virus IgG: protective level of ≥ 10 IU/mL.
- Japanese encephalitis virus IgG and IgM: evaluation of vaccine response and differential diagnosis of suspected cases.
- Hepatitis A virus IgG: confirmation of long-term immunity following vaccination or natural infection.
- Neisseria meningitidis serogroup A and C IgG with serum bactericidal antibody titers as functional correlates of protection.
Cellular Immunity and Safety Panels
- Lymphocyte subset immunophenotyping (CD3, CD4, CD8, CD19, CD16/CD56) to evaluate cellular immune competence.
- IFN-γ release assays (IGRA) and tuberculin skin test support for BCG immunization evaluation and infection screening.
- Cytokine panels (IFN-γ, IL-2, IL-4, IL-6, TNF-α) for cellular response profiling following vaccination.
- AEFI laboratory work-up: complete blood count, C-reactive protein, procalcitonin, and allergen-specific IgE screening to support causality assessment.
Testing Methods
Enzyme-Linked Immunosorbent Assay (ELISA)
Indirect and capture ELISA formats are used for qualitative and quantitative determination of IgG and IgG/IgM antibodies. Quantitative kits calibrated against WHO International Standards allow reporting in standardized units, with internal quality control sera and defined inter-assay coefficient of variation limits to ensure comparability across survey rounds.
Chemiluminescence Immunoassay (CLIA/CMIA)
Automated chemiluminescent platforms provide high-throughput anti-HBs quantification with a wide dynamic range, suitable for large population serosurveys and precise classification of high-responder, low-responder, and non-responder groups.
Microneutralization Assay for Poliovirus
The gold-standard method follows WHO polio laboratory methodology: serial two-fold serum dilutions are incubated with reference Sabin strains of poliovirus types 1, 2, and 3, followed by inoculation onto Vero or HEp-2 cell monolayers. The neutralizing antibody titer is reported as the reciprocal of the highest dilution showing complete protection from cytopathic effect.
Plaque Reduction Neutralization Test (PRNT)
PRNT with 50% endpoint calculation is applied to measles virus and Japanese encephalitis virus antibody determination, offering higher analytical specificity than ELISA and serving as the confirmatory method for equivocal ELISA results.
Toxin Neutralization and Bactericidal Assays
Diphtheria and tetanus antitoxin levels are determined by Vero cell neutralization assays, and functional meningococcal immunity is measured by serum bactericidal assay (SBA) using standardized target strains with exogenous complement.
Cellular and Molecular Methods
Flow cytometry with intracellular cytokine staining and ELISpot are used to quantify antigen-specific T-cell responses. Real-time PCR is applied to pathogen detection in surveillance specimens, and VP1 region sequencing with intratypic differentiation supports screening for vaccine-derived polioviruses.
Statistical Evaluation and Interpretation
Core indicators include seroconversion rate, seroprotection (seropositive) rate with 95% confidence intervals, geometric mean titer (GMT) or geometric mean concentration (GMC), and geometric mean fold rise between pre- and post-vaccination samples. Group comparisons use chi-square or Fisher exact tests for proportions and t-tests on log-transformed titers; survey design applies cluster sampling with adequate sample size per age stratum. Post-vaccination blood collection is conventionally scheduled 28 days or more after the final dose of the evaluated series.
Applications
- National and provincial EPI effectiveness reviews and periodic sero-epidemiological surveys of population immunity.
- Post-campaign evaluation of supplementary immunization activities and catch-up vaccination programs.
- Immunogenicity bridging studies supporting the introduction of new vaccines or changes to dosing schedules and administration routes.
- Validation of hepatitis B mother-to-child transmission interruption, combining birth-dose timeliness audits with HBsAg and anti-HBs serosurveys in target birth cohorts.
- Outbreak investigation and identification of immunity gaps through rapid serological screening of contacts and age-matched community controls.
- Cold-chain integrity audits with potency verification of retained vaccine samples following documented temperature excursions.
- Data packages for vaccine manufacturers, public health authorities, academic research, and peer-reviewed publication.
FAQ
When should blood samples be collected after the final vaccine dose?
For seroconversion and seroprotection evaluation, blood should be collected at least 28 days after the final dose of the evaluated vaccine series, since peak antibody responses generally plateau within 4 to 8 weeks after the last administration.
What is the minimum blood volume required from an infant?
A volume of 2–3 mL of venous blood is typically sufficient for a standard serological panel. Where venipuncture is impractical, dried blood spot cards requiring only a few drops of capillary blood provide a validated alternative for community-based surveys.
What does an anti-HBs result below 10 mIU/mL indicate?
A result below 10 mIU/mL is classified as non-protective. The individual may be a primary non-responder or may have experienced antibody waning over time, and additional testing for HBsAg and anti-HBc is recommended to exclude undetected infection before booster revaccination.
Why is the neutralization test preferred for poliovirus antibody evaluation?
The microneutralization assay measures functional antibodies that block viral entry into susceptible cells, which is the accepted correlate of protection, whereas binding ELISA may detect non-neutralizing antibodies and overestimate protective status.
How should serum samples be packaged and transported to the laboratory?
Serum aliquots are transported at 2–8 °C within 48 hours or frozen at −20 °C to −70 °C on dry ice for longer transit, using UN3373 Category B triple packaging with continuous temperature monitoring to preserve sample integrity.
What is the typical turnaround time for an evaluation report?
ELISA-based panels are generally reported within 7–15 working days after sample receipt, while neutralization, PRNT, and bactericidal assays requiring cell culture typically require 15–25 working days, with expedited arrangements available for outbreak response.
Which quality standards govern this evaluation service?
Testing is conducted by accredited third-party laboratories operating under ISO 15189 or ISO/IEC 17025 quality systems, with laboratory biosafety managed in accordance with ISO 15190 and assay methodologies aligned with WHO technical manuals and applicable GB and WS national standards.